Generic Bupropion XL Must Be Retested; Teva/Impax 300 mg Withdrawn After Efficacy Concerns
This article was originally published in The Pink Sheet Daily
Executive Summary
In what appears to the first downgrade of a generic equivalency based on patient complaints, FDA changes the high dose of the Teva/Impax product from AB to BX. The four other generic manufacturers of 300 mg bupropion extended-release must conduct their own bioequivalence tests, but FDA does not expect problems because they are differently formulated than the Teva/Impax version.
You may also be interested in...
FDA Pushing Forward With Withdrawal Of Two Concerta Generics
Mallinckrodt and Kremers seem prepared to fight formal notice, which comes almost two years after FDA found their methylphenidate generics failed to demonstrate bioequivalence to the Janssen's brand drug.
Concerta Generics Suit Could Illuminate FDA Bioequivalence Decision-making
FDA used ‘flawed’ method to downgrade rating, Mallinckrodt argues in defense of its top-selling product.
Two Concerta Generics Lose Therapeutic Equivalency Rating
FDA downgrades Mallinckrodt and Kudco’s methylphenidate generics from AB- to BX-rated. An influx of patient complaints about lack of efficacy spurred an investigation of the products and subsequent revision of the agency’s draft bioequivalence guidelines for the ADHD drug.